Improving seasonal and pandemic influenza vaccines.
Challenges facing seasonal and pandemic influenza vaccination include: increasing the immunogenicity of seasonal vaccines for the most vulnerable, increasing vaccination coverage against seasonal influenza, and developing vaccines against pandemic strains that are immunogenic with very low quantities of antigen to maximize the number of people who can be vaccinated with a finite production capacity. We review Sanofi Pasteur's epidemic and pandemic influenza research and development programmes with emphasis on two key projects: intradermal influenza vaccine for seasonal vaccination of both elderly and younger adults, and pandemic influenza vaccine.
Saville
Melanie
M
Research and Development Department, Sanofi Pasteur, 1541 Av. Marcel Mérieux, 69280 Marcy L Etoile, France. melanie.saville@sanofipasteur
Marsh
Grenville
G
Hoffenbach
Agnes
A
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D007114:Immunization / Q000706:statistics & numerical data; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D007271:Injections, Intradermal; D008875:Middle Aged; D055815:Young Adult
D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines